US 12,403,201 B2
B-lymphocyte specific amatoxin antibody conjugates
Torsten Hechler, Ladenburg (DE); Michael Kulke, Ladenburg (DE); and Andreas Pahl, Ladenburg (DE)
Assigned to Heidelberg Pharma Research GmbH, Ladenburg (DE)
Filed by Heidelberg Pharma Research GmbH, Ladenburg (DE)
Filed on Mar. 17, 2022, as Appl. No. 17/697,583.
Claims priority of application No. 21163784 (EP), filed on Mar. 19, 2021.
Prior Publication US 2022/0370632 A1, Nov. 24, 2022
Prior Publication US 2025/0090678 A2, Mar. 20, 2025
Int. Cl. A61K 47/68 (2017.01); A61P 35/00 (2006.01); A61P 37/06 (2006.01)
CPC A61K 47/6831 (2017.08) [A61K 47/6849 (2017.08); A61P 35/00 (2018.01); A61P 37/06 (2018.01)] 8 Claims
OG exemplary drawing
 
1. A conjugate comprising (i) a target binding moiety, (ii) at least one toxin, and (iii) at least one linker connecting said target binding moiety with said at least one toxin, wherein
said target binding moiety binds to CD37,
said at least one toxin is an amatoxin,
said target binding moiety is an antibody,
consisting of two heavy chains, each heavy chain comprising an amino acid sequence according to SEQ ID No. 11, and two light chains, each light chain comprising an amino acid sequence according to SEQ ID No. 12, as target binding moiety, conjugated to at least one amatoxin-linker moiety of formula (XII), (XIII), or (XIV) via thioether linkage of the linker with the sulfhydryl group of heavy chain 265Cys residue according to the EU numbering system of said antibody, wherein formula (XII), (XIII), or (XIV) have the structure according to:

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry
wherein n is 1 or 2.